SenseUP Bets Encapsulated RNA Can Take RNAi Pesticides Mainstream

RNA interference is one of the more elegant ideas in crop protection. It silences specific genes in a pest or pathogen, so in principle it can hit insects, fungi and other threats without the broad collateral damage of conventional chemistry. The catch has always been getting the molecule to work outside a lab dish. German startup SenseUP thinks it has found a workable route, and its co-CEO and managing director, Juan Martinez, argues the technology is ready to move from niche to mainstream.

Three problems, one platform

Martinez describes the barriers in familiar terms. Production costs were prohibitive, at least for agricultural markets, for some years. RNA also breaks down easily. And delivery is where many promising molecules stumble: a product can look excellent in vitro and then degrade quickly once it reaches a field.

SenseUP's answer is to encapsulate double-stranded RNA inside the cell wall of its host microbes, which are strains of Corynebacterium. The company says this protects the RNA and lets the product be stored at room temperature for 18 months or more in dry conditions. On cost, it uses biosensors that light up in high-producing strains, so it can screen millions of candidates and pick the best hosts quickly. The aim is biopesticides that can compete with synthetic chemicals on price. The third issue, breadth, is addressed by loading several dsRNA sequences into a single cell, so one product can target more than one pest.

Those are the claims, and they're specific enough to test. Stability, price per hectare and multi-pest efficacy are the numbers that matter to a grower, and none of them are quantified in the interview. Martinez says the company has already shown in trials that its product is stable, cost-efficient and scalable, but the source doesn't include trial data. That's the gap I'd watch.

A platform, not a single product

Most RNAi companies so far have come out of insecticides, and SenseUP wants to set itself apart. Martinez says the company has seen encouraging results in fungicides and frames the offering as a platform spanning crop protection and animal health. Its current targets include Coleoptera (beetles) and sucking pests, plus several fungi affecting grapes and potatoes. The company is also working on products for broad-acre crops.

The business model is more specific. SenseUP plans to supply the technology, product development and manufacturing, and leave commercialization, marketing and sales to partners. Martinez says the company's core strength is producing the material very cheaply. Ownership of intellectual property depends on how early each partner comes in, but SenseUP normally expects to own it. Regulatory work would be shared with partners.

That division of labour makes sense for a manufacturing-focused startup, but it also means SenseUP depends on large crop protection companies to bring products to market. Those companies, Martinez says, typically want four things: field efficacy, stability and consistency, production scalability and a clear path to registration. Consistency is the one he flags most sharply, noting that many products in the past simply didn't perform the same way from batch to batch.

The regulatory picture is shifting

Martinez points to registrations as the strongest evidence that the category is maturing. RNA-based products have already been registered in the United States, and he says one was approved in roughly nine months in Mexico, with a route also visible in Brazil.

Europe is more complicated. In May 2026, Belgium granted a 120-day emergency authorization to GreenLight Biosciences' RNAi insecticide Calantha, which uses the dsRNA active ingredient ledprona against Colorado potato beetles. That's a temporary step, not full EU approval, and the full approval is still outstanding. Longer term, the European Commission has proposed changes to EU plant protection legislation that include mechanisms meant to speed market access for agricultural biologicals. Martinez expects RNA to be treated appropriately under that framework, though the legislation is still in negotiation, so his optimism is a read on direction rather than a settled outcome.

Where it could start, and what to watch

Martinez is realistic about the commercial sequence. Biologicals typically debut on high-value crops, where growers already use them, can pay for them and face hard pest problems. That's the likely beachhead for RNAi too. SenseUP says it's already working on broad-acre products, and the real test of its cost claims will come when a product has to compete on price in those markets.

My read is that the three things to track are published field efficacy data, batch-to-batch consistency at commercial scale and the final shape of EU rules. If SenseUP can show the stability and cost numbers in peer-reviewed or independently run trials, the encapsulation approach could become a meaningful addition to the toolkit. If those numbers stay in the company's own trials, the mainstream story will be slower to arrive than the interview suggests.